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The endogenousNMDAreceptor (NMDAR) agonist D-aspartate occurs transiently in themammalianbrain because it is abundant during
embryonic andperinatal phases before drastically decreasing during adulthood. It iswell established that postnatal reduction of cerebral
D-aspartate levels is due to the concomitant onset of D-aspartate oxidase (DDO) activity, a flavoenzyme that selectively degrades bicar-
boxylic D-amino acids. In the presentwork,we show that D-aspartate content in themouse brain drastically decreases after birth, whereas
DdomRNA levels concomitantly increase. Interestingly, postnatalDdo gene expression is paralleledbyprogressive demethylationwithin
its putative promoter region. Consistent with an epigenetic control on Ddo expression, treatment with the DNA-demethylating agent,
azacitidine, causes increased mRNA levels in embryonic cortical neurons. To indirectly evaluate the effect of a putative persistent Ddo
gene hypermethylation in the brain, we used Ddo knock-out mice (Ddo/), which show constitutively suppressed Ddo expression. In
these mice, we found for the first time substantially increased extracellular content of D-aspartate in the brain. In line with detrimental
effects produced by NMDAR overstimulation, persistent elevation of D-aspartate levels in Ddo/ brains is associated with appearance
of dystrophic microglia, precocious caspase-3 activation, and cell death in cortical pyramidal neurons and dopaminergic neurons of the
substantia nigra pars compacta. This evidence, alongwith the early accumulation of lipufuscin granules inDdo/ brains, highlights an
unexpected importance of Ddo demethylation in preventing neurodegenerative processes produced by nonphysiological extracellular
levels of free D-aspartate.
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Significance Statement
The enzyme D-aspartate oxidase (DDO) catalyzes the degradation of the NMDA receptor agonist, D-aspartate. In the brain, DDO is
expressed only during postnatal life, thus reducing the embryonic storage of D-aspartate and keeping this D-amino acid at low
levels during adulthood. Although the presence of DDO in mammals is long established, its biological role in the brain and the
mechanism regulating its expression are still unclear. Here, we found that Ddo promoter demethylation enables the postnatal
expression of Ddo. Moreover, persistent suppression of Ddo expression leads to persistent spillover of extracellular D-aspartate
and produces precocious cell death in themouse brain, thus suggesting a key role for DDO in preventing early neurodegeneration
triggered by excessive NMDA receptor stimulation.
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Introduction
Since the first discovery by SirHansKrebs in 1935, the presence of
flavoproteins responsible for D-amino acids’ deamination
(Krebs, 1935; Still and Buell, 1949) is well known inmammals. In
particular, D-aspartate oxidase (DDO or DASPO, EC 1.4.3.1) is a
FAD-containing enzyme that selectively deaminates bicarbox-
ylic D-amino acids, such as D-aspartate (D-Asp), NMDA, and
D-glutamate (Still and Buell, 1949; Van Veldhoven et al., 1991;
D’Aniello et al., 1993).DDO is expressed in both humans and rats
(Van Veldhoven et al., 1991; Schell et al., 1997; Zaar et al., 2002).
In the rat brain, DDO activity is nearly absent during embryonic
and perinatal stages and progressively increases during adult-
hood (Van Veldhoven et al., 1991). Accordingly, free D-Asp
(DDO endogenous substrate) shows a reciprocal temporal oc-
currence because it is substantially enriched in the embryonic
brain, rapidly declines after birth, and remains at low levels
throughout the adulthood (Dunlop et al., 1986; Neidle and Dun-
lop, 1990; Hashimoto et al., 1993, 1995; Sakai et al., 1998; Wolo-
sker et al., 2000). Notably, in homogenates from human fetal
prefrontal cortex (PFC), the amount of free D-Asp even exceeds
that of the L-aspartate (L-Asp) at gestational week 14, before sub-
stantially decreasing at postnatal stages (Hashimoto et al., 1993).
The peculiar temporal pattern ofDDOexpression in the rat brain
suggests that this catabolic enzyme acts to maintain low levels of
D-Asp during postnatal brain development. However, the biolog-
ical meaning of the prominent postnatal DDO activity is still
unclear. Likewise, it is still unknown whether abundant free
D-Asp levels play any physiological role during embryonic and
perinatal brain development. Recent evidence frommouse brain
tissue slices has shown that free D-Asp activates the NMDA re-
ceptors (NMDARs) via binding to the GluN2 subunit (Errico et
al., 2008a, b; 2011a, b). In this line, studies performed in mice
lacking theDdo gene (Ddo/) and in chronically D-Asp-treated
mice have demonstrated that the resulting increase in free D-Asp
in the brain (Errico et al., 2006; Huang et al., 2006) affects
NMDAR-dependent transmission (Errico et al., 2008a, b, 2011a,
b, 2014; Krashia et al., 2015), early- and late-phase hippocampal
LTP (Errico et al., 2008b, 2014), dendritic length and spine den-
sity of hippocampal and cortical neurons (Errico et al., 2014), and
spatial memory abilities (Errico et al., 2008a, 2011a, b). Further-
more, higher levels of D-Asp in Ddo/mice are also associated
with greater brain connectivity, as well as reduced sensorimotor
gating deficits and abnormal circuits activation induced by the
hallucinogenic drug, phencyclidine, as assessed by fMRI (Errico
et al., 2015b). Consistent with these findings in mice, a human
DDO gene variant (rs3757351), yielding reduced expression lev-
els ofDDOmRNA in postmortem prefrontal cortex, is associated
with both greater prefrontal graymatter and activity (fMRI) dur-
ing workingmemory processing in healthy subjects (Errico et al.,
2014).
Based on the basic and translational interest of free D-amino
acids in brain physiology and in the treatment of psychiatric dis-
orders, such as schizophrenia (Tsai et al., 1998, 2006; Heresco-
Levy et al., 2005; Lane et al., 2005; Kantrowitz et al., 2010), we aim
here to do the following: (1) elucidate the molecular mechanism
regulating the postnatal cerebral expression of DDO; (2) investi-
gate how the targeted deletion ofDdo affects extracellular levels of
free D-Asp in the brain; and (3) clarify the physiological relevance
of this enzyme in the mammalian brain during aging.
Materials andMethods
Animals. All experiments were performed on male animals. C57BL/6J
mice were purchased from The Jackson Laboratory. Knock-out mice for
the Ddo gene were generated and genotyped by PCR as described previ-
ously (Errico et al., 2006).Wild-type (Ddo/) and knock-out (Ddo/)
mice, derived from mating of heterozygous (Ddo/) mice, were back-
crossed to the F5 generation to C57BL/6J strain. Mice were housed in
groups (n 4 or 5) in standard cages (29 17.5 12.5 cm) at constant
temperature (22  1°C) and maintained on a 12/12 h light/dark cycle,
with food and water ad libitum. All research involving animals was per-
formed in accordance with the European directive 86/609/EEC govern-
ing animal welfare and protection, which is acknowledged by the Italian
Legislative Decree no. 116 (January 27, 1992). Animal research protocols
were also reviewed and consented to by a local animal care committee. All
efforts were made to minimize the animal’s suffering.
Mouse tissue collection. Whole brains were collected from C57BL/6J
mice at different developmental stages, including the following time
points: embryonic day 15 (E15; n  5), postnatal day 0 (P0; n  2), P7
(n 3), P14 (n 6), P21 (n 3), P30 (n 3), and P60 (n 3). The PFC
and ventral midbrain were dissected out from 3-month-oldDdo/ and
Ddo/ mice (PFC, n  5/genotype; midbrain, n  4/genotype). Mice
were killed, and the whole brain, PFC, or midbrain was dissected out
within 20 s on an ice-cold surface. All tissue samples were pulverized in
liquid nitrogen and stored at80°C for subsequent processing.
HPLC analyses. Brain tissue samples were analyzed as previously re-
ported (Topo et al., 2010), withminormodifications. They were homog-
enized in 1:20 (w/v) 0.2 M TCA, sonicated (3 cycles, 10 s each), and
centrifuged at 10,000  g for 10 min. The precipitated protein pellets
were stored at 80°C for protein quantification, whereas the superna-
tants were neutralized with NaOH and subjected to precolumn derivati-
zation with o-phthaldialdehyde (OPA)/N-acetyl-L-cysteine in 50%
methanol. Enantiomer derivatives were then resolved on a Simmetry C8
5 m reversed-phase column (Waters, 4.6 250 mm), in isocratic con-
ditions (0.1 M sodium acetate buffer, pH 6.2, 1% tetrahydrofuran, 1
ml/min flow rate). A washing step in 0.1 M sodium acetate buffer, 3%
tetrahydrofuran and 47% acetonitrile, was performed after every single
run. Identification and quantification of D-and L-Asp was based on re-
tention times and peak areas, compared with those associated with ex-
ternal standards. The two enantiomers were detected as well-defined
peaks at the retention time of 4.75  0.1 min and 5.33  0.1 min for
D-and L-Asp, respectively (see Fig. 1a,b). The identity of D-Asp and L-Asp
peaks was confirmed either by the selective degradation catalyzed by the
RgDAAO M213R variant (Sacchi et al., 2002) (see Fig. 1a, inset) and
StLASPO (Bifulco et al., 2013), respectively, or by the addition of external
standards (see Fig. 1b, inset). The samples were added with 10 g of the
enzymes, incubated at 30°C for 30min, and then derivatized (Topo et al.,
2010). Total protein content of homogenates was determined using the
Bradford assay method after resolubilization of the TCA precipitated
protein pellets. The detected total concentration of D-Asp and L-Asp in
homogenates was normalized by the total protein content. Data on the
ontogenetic occurrence of D-and L-Asp in the whole brain were analyzed
by one-way ANOVA (age effect); data on D-and L-Asp occurrence in the
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PFC and midbrain of Ddo/ and Ddo/ mice were analyzed by Stu-
dent’s t test (genotype effect).
Dialysates were analyzed for D-Asp, L-Asp, and L-Glu content, as pre-
viously described (Guida et al., 2015). The HPLC system comprised a
Varian ternary pump (model 9010), a C18 reverse-phase column, a Var-
ian refrigerated autoinjector (model 9100), and a Varian fluorimetric
detector. Dialysates were precolumn derivatized with OPA (10 l dialy-
sate 10 l OPA) and amino acid conjugates resolved using a gradient
separation. The mobile phase consisted of the following two compo-
nents: (1) 0.2 M sodium phosphate buffer, pH 5.8, 0.1 M citric acid, pH
5.8; and (2) 90% acetonitrile. The identity of D-Asp peak was confirmed
by incubating a parallel sample with 20g of purified DDO (Negri et al.,
1999) for 15 min at 37°C and chromatographed as above. Identification
and quantification of D-and L-Asp, as well as L-Glu, were performed as
reported above.Datawere collected by aDell PC system310 interfaced by
Varian Star 6.2 control data and acquisition software. Amino acid extra-
cellular levels were expressed as nM (D-Asp and L-Asp) or M (L-Glu)
concentration. Data were analyzed by two-way ANOVA with repeated
measures (genotype time).
Enzymes. Recombinant Rhodotorula gracilis D-amino acid oxidase
M213R variant (RgDAAO M213R; EC 1.4.3.3) and Sulfolobus tokodaii
L-aspartate oxidase (StLASPO; EC 1.4.3.16) were overexpressed in Esch-
erichia coli cells and purified as previously described (Sacchi et al., 2002;
Bifulco et al., 2013). Final RgDAAO M213R and StLASPO preparations
had a specific activity of 5.8 U/mg protein on D-Asp as substrate and 0.98
U/mg protein on L-Asp as substrate, respectively, whereas they were fully
inactive on the opposite enantiomers. Recombinant DDO (EC 1.4.3.1)
from beef kidney was expressed in E. coli, and the purified preparation
showed a specific activity of 5 U/mg protein (Negri et al., 1999).
In vivo microdialysis. Microdialysis experiments were performed in
awake and freelymovingmice as previously reported (Guida et al., 2015).
Three-month-old Ddo/ and Ddo/ mice were anesthetized with
pentobarbital (50 mg/kg, i.p.), and the concentric microdialysis probes
were stereotaxically implanted into the PFC area (anteroposterior: 1.5
mm; L: 0.3; and ventral: 3.3 mm below the dura) and secured to the skull
using stainless steel screws and dental cement. Microdialysis probes were
constructedwith 22G (0.41mm I.D., 0.7mmO.D.) stainless steel tubing:
inlet and outlet cannulae (0.04 mm I.D., 0.14 mm O.D.) consisted of
fused silica tubing. The probe had a tubular dialysis membrane (Enka)
1.3mm in length. After a postoperative recovery period of48 h, dialysis
was commencedwith ACSF (147mMNaCl, 2.2mMCaCl2, 4mMKCl, pH
7.2). Animals were perfused at a rate of 1.2 l/min using a Harvard
Apparatus infusion pump (model 22). After an equilibration period of 60
min, samples were collected every 30 min for a total time length of 180
min. The last dialysate fraction (150–180 min) was collected in the ab-
sence of calcium by perfusing with Ca2-free ACSF solution. Dialysates
were analyzed for D-Asp, L-Asp, and L-Glu content using HPLC coupled
with the fluorimetric detection method.
In situ hybridization (ISH). ISH analysis was performed on sagittal
sections from E15, P0, P14, P30, and P60 C57BL/6J brains (n  3 per
age), Ddo/ or Ddo/ brains (n  3 per genotype) according to a
protocol previously described (Migliarini et al., 2013). 35S-labeled Ddo
antisense riboprobes (1.9 kb) were used. Hybridized sections were ex-
posed to BiomaxMR x-ray films (Kodak) for 7–9 d. Sections were exam-
ined using brightfield light microscopy. To obtain clearer and more
defined images, less disturbed by the background noise, pseudocolor
scale of the images was used. Signals were pseudocolored with the Na-
tional Institutes of Health ImageJ Lookup Table 16_colors.
RNA extraction and qRT-PCR. Total RNA was extracted by TRIZOL
reagents (Ambion, Invitrogen) according to the manufacturer’s instruc-
tions. The integrity of the RNA was assessed by denaturing agarose gel
electrophoresis (presence of sharp 28S, 18S, and 5S bands) and spectro-
photometry (NanoDrop 2000, Thermo Scientific). Total RNA was puri-
fied to eliminate potentially contaminating genomic DNA using
recombinant DNase (QIAGEN). A total of 1 g of total RNA of each
sample was reverse-transcribed with QuantiTect Reverse Transcription
(QIAGEN) using oligo-dT and random primers according to the manu-
facturer’s instructions. qRT-PCR amplifications were performed using
LightCycler 480 SYBR Green I Master (Roche Diagnostic) in a LightCy-
cler 480 Real Time thermocycler (Roche). The following protocol was
used: 10 s for initial denaturation at 95°C followed by 40 cycles consisting
of 10 s at 94°C for denaturation, 10 s at 60°C for annealing, and 6 s for
elongation at 72°C temperature. The following primers were used for
mouse Ddo cDNA amplification: Ddo forward 5-ACCACCAGTAATG
TAGCGGC3 andDdo reverse 5-GGTACCGGGGTATCTGCAC-3;-ac-
tin gene was used as housekeeping gene forPCR: -actin forward 5-CT
AAGGCCAACCGTGAAAAG-3 and -actin reverse 5-ACCAG
AGGCATACAGGGACA-3. Data were analyzed by one-way ANOVA (age
effect).
5-Aza-2-deoxycytidine treatment of primary cortical neurons. Cortical
neurons were prepared from brains of 17-day-old C57BL/6J mouse em-
bryos as previously described (Sisalli et al., 2014). Briefly, the mice were
first anesthetized and then killed by cervical dislocation to minimize the
animals’ pain and distress. Dissection and dissociation were performed
in Ca2/Mg2-free buffer saline (HBSS 1). Tissues were incubated
with trypsin for 20 min at 37°C and dissociated by trituration in culture
medium. Cells were plated at 3.5–5 106 in 60 mm plastic Petri dishes,
precoated with poly-D-lysine (20 mg/ml), in MEM/F12 (Invitrogen)-
containing glucose, 5% deactivated FBS, and 5% horse serum (Invitro-
gen), glutamine, and antibiotics. Ara-C (10mM)was addedwithin 48 h of
plating to prevent non-neuronal cell growth. Neurons were cultured at
37°C in a humidified 5% CO2 atmosphere. Forty-eight hours of treat-
ment of neuronal cultures was done with 5-aza-2-deoxycytidine at a
final concentration of 5 M (Sigma-Aldrich). All the experiments on
primary cortical neurons were performed according to the procedures
described in experimental protocols approved by the Ethical Committee
of the Federico II University of Naples. RNA extraction and qRT-PCR
were performed as described above.
DNA extraction and methylation analysis. DNA from frozen brain tis-
sue samples was extracted using the ZR Genomic DNA tissue Midi Prep
kit (Zymo Research). The integrity and the amount of genomic DNA
were assessed by 0.8% agarose gel electrophoresis and Qubit Fluoromet-
ric Quantitation (Invitrogen). Sodium bisulfite conversion was per-
formed using EZDNAMethylation Kit (Zymo Research). A total of 2g
of genomic DNA was used according to the manufacturer’s instruction.
Methylation status was assessed through a strategy based on the locus-
specific amplification of bisulfite-treated genomicDNA, amplifying each
amplicon separately, followed by Illumina MiSeq sequencing. Fusion
primers were designed to generate tiled amplicons ranging in size
between 400 and 500 bp segments. Sequence of the bisulfite-specific
primers used for this analysis were as follows: Ddo PR1 forward 5-
gtgtgtttTtgaggaggtgaTaTtTa-3 (nt position from 468 to 444) and
Ddo PR1 reverse 5-aActtaccctccattAAtccatAcc-3 (nt 88 to 63) for
theDdo promoter region 1 (amplicon size 405 bp) andDdo PR2 forward
5-ggTtggtggTaagTtgaagttTttg-3 (nt 229 to 204) and Ddo PR2 re-
verse 5-acccctaaaatcccaAaAtAcatac-3 (nt 118 to 143) for the Ddo pro-
moter region 2 (amplicon size 372). The capital letters in the primers
sequences indicate the original C or G, respectively. The methods in-
volved two PCR steps, following Illumina recommended procedure. The
pool of amplicons was subjected to sequencing using MiSeq system (V3
reagents kits). Sequencing was performed by 281 2 cycles (paired-end
sequencing). Sequences in FASTQ format by Illumina sequencing ma-
chine were initially processed with Paired-End reAd mergeR (PEAR)
data for an initial quality filtering and assembling (R1 plus R2). Only
those sequences with a threshold quality score of 30, a read length
between 400 and 500 nt, and an overlapping region within paired-end
reads of 40 nt were processed with PReprocessing and INformation of
SEQuence (Prinseq) to obtain FASTA for further analysis. On average,
232,000 (range: 139,241–368,083) amplicon reads were obtained from
each sample. Reads were aligned to the bisulfite converted reference se-
quence. Methylation states were estimated by observing base calls (T/C)
at CpG sites in themapped reads. Reads with ambiguous calls at the CpG
dinucleotide were removed. After filtering, an average of 200,000
(range: 119,040–317,832) amplicon reads were obtained from each sam-
ple. Data were analyzed by one-way ANOVA (age effect).
Immunohistochemistry. Ddo/ andDdo/mice at 0.5, 3, 6, 10, and
13 months of age (n 3 per genotype and age) were deeply anesthetized
and transcardially perfused with a saline solution followed by 4% PFA in
3066 • J. Neurosci., March 9, 2016 • 36(10):3064–3078 Punzo et al. • DdoMethylation Controls Cell Death during Aging
0.1 M phosphate buffer. Morphological investigation of microglia was
performed by incubation of sections with rabbit anti-Iba-1 primary an-
tibody (1:1000 anti-ionized calcium-binding adapter molecule 1; Wako
Chemicals) and revealed by appropriate secondary antibody (goat anti-
rabbit, IgG-conjugated AlexaFluor-488; 1:1000; Invitrogen). The analy-
sis of microglia was performed as previously described (Cristino et al.,
2015). Briefly, quantitative analysis was performed by counting, for each
phenotype, the bisbenzimide-counterstained cells with nucleus on the
focal plane within a box measuring 2 104 m2 in the substantia nigra
pars compacta (SN). Resting microglia displayed small somata bearing
long, thin, ramified processes. Activatedmicroglia exhibitedmarked cel-
lular hypertrophy and retraction of processes such that the process length
was less than the diameter of the soma compartment. Dystrophic micro-
glia was recognized by debris consisting of cells displaying fragmented
processes as previously demonstrated in humans (Streit et al., 2009,
2014).
Moreover, serial 10 m PFC and SN frozen sections were collected
onto glass slides (Menzel) to be processed for Neuronal Nuclear (NeuN)
marker immunoperoxidase (PFC) and for activated caspase-3/NeuN
(PFC), or activated caspase-3/tyrosine hydroxylase (TH) (SN) immuno-
fluorescence counterstained with DAPI. For NeuN immunoperoxidase
staining, the PFC sections were reacted for 10 min in 0.1% H2O2 to
inactivate endogenous peroxidase activity and then incubated with 10%
normal goat serum (Vector Laboratories) in 0.1 M Tris-buffered saline,
pH 7.6, containing 0.3% Triton X-100 and 0.05% sodium azide (Sigma).
The sections were then incubated overnight at 4°C with normal goat
serum diluted (range 1:200–1:400) rabbit polyclonal anti-NeuN (Ab-
cam). After several rinses, the sections were incubated at room temper-
ature for 2 h in biotinylated goat anti-rabbit IgGs (Vector Laboratories)
followed 1 h by incubation in the avidin-biotin complex (ABC Kit; Vec-
tastain, Vector) diluted in Tris-buffered saline according to the
manufacturer’s indications and then in 0.05% DAB for 10 min (DAB
Sigma Fast, Sigma-Aldrich). Immunohistochemical study of activated
caspase-3 in PFC and SN was performed by incubation with goat anti-
activated caspase-3 (Santa Cruz Biotechnology) revealed by specific
Alexa-488 secondary donkey anti-IgG antibody (Invitrogen) counter-
stained with DAPI. For activated caspase-3/NeuN or caspase-3/TH im-
munofluorescence, the sections were incubated with a mixture of goat
anti-active caspase-3 (Santa Cruz Biotechnology) with rabbit polyclonal
anti-NeuN (Abcam) or mouse anti-TH (Abcam) and revealed by a mix-
ture of Alexa-488 and Alexa-546 secondary donkey anti-IgG antibodies
(Invitrogen). TUNEL assay was performed on n 3 sections (each from
the rostral, medial, and caudal level of PFC or SN to be representative of
the entire region) by using a commercial kit (Merck,Millipore) in accor-
dancewith themanufacturer’s instructions. Caspase-3 andTUNEL assay
were analyzed by Leica DMI6000microscope equipped with appropriate
filters and deconvolution MetaMorph LAS AF 2.2.0 software (Leica).
Quantitative analysis was performed by counting the activated caspase-
3-positive cells in 6.25 104m2of PFCarea/section (n 3 sections per
animal) and activated caspase-3/TH-positive neurons on n 200 20
randomly selected TH-immunoreactive neurons (n 4 SN sections per
each genotype and age). Furthermore, activated caspase-3/NeuN-
positive neurons were counted on n 200 20 NeuN-immunoreactive
neurons randomly selected (n  3 PFC sections per genotype of 13
month-old mice). Statistical analysis was performed by two-way
ANOVA (genotype age), followed by Fisher’s post hoc analysis between
genotypes, when required.
Lipofuscin quantification. Sagittal 100-m-thick Vibratome-cut sec-
tions obtained from Ddo/ and Ddo/ PFA-fixed brains at 0.5 and 3
months of age (n  3 per genotype and age) were used. Free-floating
sections were incubated with mouse anti-TH and subsequently with an
Oregon Green 488 goat anti-mouse secondary antibody (Invitrogen) to
label dopaminergic neurons, and counterstained with DAPI to identify
cortical layers. For each animal, 7–10 images at the level of the SN and of
the PFC (layer V-VI) were acquired for the DAPI, red, and green chan-
nels at 60 magnification with a Nikon A1 confocal microscope. Each
image was a projection of a Z-stack with 20 Z-steps at 0.5 m intervals.
Lipofuscin inclusion bodies were visualized as red autofluorescent gran-
ules with the 561 nm laser excitation and analysis of their volume was
performed using Imaris 7.2.3 software (Bitplane, Scientific Software).
Results
Age-related decrease in D-aspartate levels mirrors progressive
increased expression inDdomRNA in the mouse brain
It has been reported that in the human and rat brain free D-Asp
concentration decreases after birth and remains at low levels
throughout postnatal life (Hashimoto et al., 1993; Schell et al.,
1997; Sakai et al., 1998; Wolosker et al., 2000). Here we sought to
investigate whether such ontogenetic variations occur also in the
mouse brain. In this regard,we quantified the content of both free
D-Asp and L-Asp in brain homogenates at different time points,
between embryonic day 15 (E15) and adult postnatal day 60
(P60) by HPLC. At E15, the concentration of D-Asp and L-Asp
detected in whole-brain homogenates were 5.10  0.63 and
25.33 4.13 nmol/mg protein, respectively. Consistently to hu-
mans and rats (Dunlop et al., 1986; Neidle and Dunlop, 1990;
Hashimoto et al., 1993, 1995; Sakai et al., 1998; Wolosker et al.,
2000), free D-Asp content in the mouse brain decreased signifi-
cantly after birth (one-way ANOVA, F(6,18) 9.394; p	 0.0001;
Fig. 1c). Post hoc comparison revealed a significant drop in free
D-Asp concentration at P7 (3.45  0.20 nmol/mg protein; p 
0.0192, compared with E15), followed by a progressive decrease
at subsequent developmental stages until P60 (1.81  0.28
nmol/mg protein; p  0.0343, compared with P7; p 	 0.0001,
compared with E15; Fig. 1c). On the other hand, no changes were
detected in free L-Asp levels at the analyzed ages (F(6,18) 0.586;
p 0.7374; Fig. 1d). Accordingly, the calculated D-Asp/total Asp
ratio showed the same reduction profile observed for D-Asp dur-
ing postnatal development (F(6,18) 4.215; p 0.0080; Fig. 1e).
At the same prenatal and postnatal time points, we also inves-
tigated Ddo gene expression by qRT-PCR (Fig. 1f). Notably, the
DdomRNA in the whole brain strongly increased during postna-
tal development (one-way ANOVA, F(6,14)  14.751; p 	
0.0001). In particular, the relative expression of Ddo transcript
was very low at E15 and P0 (0.03 0.01 and 0.07 0.02, respec-
tively), and progressively raised during postnatal stages, reaching
a25-fold increase at P60, compared with E15 (0.85 0.10; p	
0.0001, Fisher’s post hoc) (Fig. 1f). Finally, we evaluated the spa-
tial pattern ofDdomRNA transcriptional activation in themouse
brain during ontogenesis by 35S radioactive ISH (Fig. 1g). At E15
and P0, DdomRNA expression was detected within the ependy-
mal cell layer of the telencephalic ventricles. At P14, several brain
regions, such as the hippocampus, thalamus, and cerebellum,
displayed intense Ddo mRNA expression in addition to the
ependymal cell layer. At P30 and, more robustly at P60, Ddo
transcript levels strongly increased in these areas and appeared
pronounced also in the midbrain region, pons, olfactory bulbs,
and cortex. In addition to high-intensity signal in specific re-
gional districts, we observed in adults a widespread expression of
DdomRNA throughout the brain.
The state of methylation of theDdo promoter controlsDdo
mRNA expression in the mouse brain
The temporal increase of Ddo transcript levels observed by qRT-
PCR and ISH (Fig. 1f,g) is coherent with the progressive global
decrease of free D-Asp found in the brain during the postnatal life
(Fig. 1c). This evidence prompted us to investigate the regulatory
mechanism of Ddo expression in the mouse brain. In particular,
we evaluated whether the age-related increase in cerebral Ddo
mRNA could be explained by epigeneticmodifications occurring
during the late phases of embryogenesis and/or the early postna-
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Figure 1. Variation in D-aspartate levels and Ddo mRNA expression in the mouse brain during ontogenesis. a, b, Examples of HPLC chromatograms illustrating the detection of (1)
D-aspartate (D-Asp) and (2) L-aspartate (L-Asp) obtained from (a) E15 and (b) P90 brain tissue samples. The identity of the peak corresponding to D-aspartate (4.66 0.09 min) was
verified by treating E15 samples with 10g RgDAAOM213R (a, inset, dotted line), and by adding the external standard to P90 samples (b, inset, dotted line). D-Aspartate retention time
is reported as the mean SD; n 34. c– e, Average content of D-aspartate, L-aspartate, and D-aspartate/total aspartate ratio in total brain of C57BL/6J mice at different ages (E15, n
5; P0, n 2; P7, n 3; P14, n 6; P21, P30, and P60, n 3). The amount of (c) D-aspartate and (d) L-aspartate in the brain homogenates, detected by HPLC, was normalized by the
total protein content of each sample. f, Analysis of Ddo mRNA expression performed by qRT-PCR on a different set of whole brains from C57BL/6J mice at different ages (n 3 per age).
Quantity means of transcript were normalized to-actin housekeeping gene. **p	 0.01 (one-way repeated-measures ANOVA). ***p	 0.0001 (one-way repeated-measures ANOVA).
Data are mean SEM. g, Representative pseudocolor autoradiographs from sagittal sections throughout the mouse brain at E15, P0, P14, P30, and P60 showing Ddo mRNA expression
pattern. The relationship between autoradiographic signal intensity (from 0 to 255) and the pseudocolor images is scaled by pseudocolor bars (from blue to white). Scale bar, 750m.
V, Ependymal cell layer of the ventricle; CA, cornu ammonis area; Ce, cerebellum; DG, dentate gyrus; Th, thalamus; Po, pons; C, cortex; Ob, olfactory bulb.
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tal stages of development. In this regard, we investigated the
methylation state of the putative promoter region of theDdo gene
at different prenatal and postnatal developmental stages, from
E15 to P60, using the same whole brain samples tested for Ddo
mRNA quantification (Fig. 1f). DNA methylation analysis was
assessed through a strategy based on the locus-specific amplifica-
tion of bisulfite-treated genomic DNA.We covered two overlap-
ping genomic regions surrounding the transcription start site
(TSS): Ddo regulatory region 1 (RR1), spanning nucleotides
443 to 88 and including 6 CpG sites (positions 363, 330,
318, 242, 175, 125), and Ddo regulatory region 2 (RR2)
spanning nucleotides 185 to 150 and including 4 CpG sites
(positions175,125, 50, 113), the first two of which coincided
with the last two located most 3 in RR1 (Fig. 2a). At each CpG
site, we observed that the methylation degree progressively de-
creased from E15 to adult stages (one-way ANOVA, p 0.0003
for CpG 113, p 	 0.0001 for all other CpG sites) (Fig. 2b). On
average, the methylation state of the 8 CpG sites lying in the Ddo
gene region from nucleotides 363 to 113 gradually decreased
from60% in E15 brains to30% at P21-P60 stages (F(6,14)
39.887; p	 0.0001; Fig. 2c). Overall, these results for the first time
highlight the occurrence of a developmentally regulated DNA
demethylation process at the putative Ddo gene promoter.
To assess whether the progressive demethylation of the Ddo
regulatory region could influence the gradual postnatal increase
in Ddo mRNA levels, we then investigated whether “forced” al-
teration in DNA methylation state was linked to variations in
cerebral Ddo expression. To this aim, we treated E17 cortical
neurons (inwhichDdo transcript is at the lowest expression level)
either with vehicle or 5M 5-aza-2-deoxycytidine (azacitidine), a
drug known to promote DNA demethylation both in cycling and
in postmitotic cells (Marutha Ravindran andTicku, 2005;Nelson
et al., 2008; Gavin et al., 2013). Consistent with an epigenetic
control of DNA methylation on Ddo mRNA transcription,
qRT-PCR analysis showed that treatment with azacitidine
caused an 4-fold increase in transcriptional levels of Ddo
(relative expression: 3.97  0.93), compared with vehicle-
treated neurons (Fig. 2d).
Absence of DDO is associated with higher extracellular
concentration of free D-aspartate in the brain ofDdo/mice
In the attempt to decipher the physiological relevance of the post-
natal Ddo promoter demethylation and, in turn, the influence of
the concomitant DdomRNA upregulation on free D-Asp occur-
rence, we analyzed the neurochemical features of Ddo/ adult
brains.Weused this animalmodel because itmaintains, along the
entire postnatal life, the physiological condition occurring during
embryonic stages, when cerebral Ddo expression is suppressed
and free D-Asp is abundant. Consistently, our 35S-radioactive
ISH revealed that E15 Ddo/ and Ddo/ brains were almost
indistinguishable, as Ddo mRNA appeared barely detectable in
both genotypes; in contrast, at P60,Ddo/brainsmaintained an
“embryo-like” inconsistent Ddo expression, whereas Ddo/
brains displayed robust and widespread Ddo mRNA detection
(Fig. 3a).
Based on the lack of Ddo expression in knock-out brains, we
measured the total amount of free D-Asp and L-Asp in the PFC of
Ddo/ mice. As previously reported in other brain regions
(Errico et al., 2006; Huang et al., 2006; Han et al., 2015), HPLC
analysis indicated that also in the PFC the deletion of the Ddo
gene yielded a strong increase in total D-Asp levels, compared
with controls (30-fold) (Ddo/: 0.49  0.04 nmol/mg pro-
tein, Ddo/: 15.91  1.46 nmol/mg protein; p 	 0.0001, Stu-
dent’s t test; Fig. 3b), whereas L-Asp content remained unchanged
between genotypes (Ddo/: 25.88  2.10 nmol/mg protein,
Ddo/: 25.37 1.21 nmol/mg protein; p 0.8397; Fig. 3c). In
agreement with these detections, an increase of the same magni-
tude as for D-Asp was also found for the D-Asp/total Asp ratio in
Ddo/ mice, compared with Ddo/ littermates (Ddo/:
0.019 0.001, Ddo/: 0.38 0.02; p	 0.0001; Fig. 3d).
Then, we measured free D-Asp extracellular levels in the PFC
of freelymovingDdo/ andDdo/mice by in vivomicrodialy-
sis, followed by HPLC analysis of the collected perfusates, as re-
ported by Guida et al. (2015). Remarkably, we found that lack of
Ddo resulted in significantly5-fold higher free D-Asp extracel-
lular levels in the cortical perfusates of Ddo/ mice, compared
with Ddo/ animals (mean values: Ddo/, 18.26  4.40 nM;
Ddo/, 101.50 8.41 nM; two-wayANOVAwith repeatedmea-
sures, genotype effect: F(1,56) 20.034, p 0.0005; Fig. 3e). We
finally collected the last dialysate fraction (150–180 min) in
Ca2-free ACSF. Interestingly, under this condition, extracellu-
lar concentration of D-Asp was below the detection limit in both
Ddo/ and Ddo/mice, suggesting that the removal of Ca2
from the ACSF is able to prevent the cortical efflux of free D-Asp
(Fig. 3e). In addition to D-Asp, we also detected the extracellular
cortical concentration of free L-Asp and L-Glu. Surprisingly, de-
spite that total L-Asp content was comparable between genotypes
(Fig. 3c), a significant 2-fold increase of extracellular L-Asp
levels was apparent in the PFC of Ddo/ mice, compared with
wild-type ones (mean values:Ddo/, 84.00 2.44 nM;Ddo/,
177.16  8.74 nM; F(1,56)  14.954, p  0.0017; Fig. 3f). On the
other hand, extracellular L-Glu concentrations detected in corti-
cal perfusates were comparable between genotypes (mean values:
Ddo/, 1.02  0.03 M, Ddo/, 0.86  0.03 M; F(1,32) 
0.399, p  0.5451; Fig. 3g). As observed for D-Asp, extracellular
levels of both L-Asp and L-Glu were undetectable when microdi-
alysis was performed in a Ca2-free ACSF (Fig. 3f,g).
Nonphysiological increase of D-aspartate inDdo/ brains is
associated with age-related caspase-3 activation and cell death
in the prefrontal cortex
Several works have indicated that free D-Asp activates NMDAR-
dependent signaling and currents (Errico et al., 2015b). On the
other hand, it is known that persistent stimulation ofNMDARs at
extrasynaptic site triggers oxidative stress and the activation of
apoptotic/necrotic pathways (Lipton, 2008; Hardingham and
Bading, 2010; Parsons and Raymond, 2014). Here, we examined
whether constitutive exposure of cortical neurons to nonphysi-
ological, higher extracellular D-Asp levels produces neurotoxic
effects in the brain of Ddo/ mice during aging. Considering
that caspase activation plays a pivotal role in neuronal apoptosis
and represents the terminal event preceding cell death (Shalini et
al., 2015), we measured the expression of active caspase-3 and
DNA fragmentation by TUNEL staining in the infralimbic/pre-
limbic area of the PFC in Ddo/mice at 3, 6, and 13 months of
age (Fig. 4). Two-way ANOVA revealed a significant age-
dependent increase of caspase-3 activation in Ddo/mice (ge-
notype, F(1,12) 1236.720, p	 0.0001; genotype age, F(2,12)
336.130, p 	 0.0001). More in detail, in line with detrimental
effects of nonphysiological NMDAR stimulation produced by
higher extracellular free D-Asp levels, we found a significantly
increased percentage of activated caspase-3-positive cells in 6-
and 13-month-old Ddo/ mice, compared with age-matched
controls (6-month-old:Ddo/, 27.98 0.59,Ddo/, 62.87
1.27; p	 0.0001; 13-month-old:Ddo/, 26.29 0.55,Ddo/,
71.51  0.55; p 	 0.0001; Fisher’s post hoc; Fig. 4a,b). The in-
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crease of percentage of activated caspase-3-positive cells was
mainly attributed to the pyramidal neurons of the PFC as ob-
served by a reduction of the number of NeuN-immunoreactive
profile and by increased percentage of activated caspase-3/
NeuN immunocoexpression within the NeuN-positive neu-
rons of 13-month-old Ddo/mice (Ddo/, 20.56 2.04%,
Ddo/, 67.45  2.30%; p 	 0.0001; Student’s t test; Fig. 4a,
bottom panels).
In agreement with the substantial increase of active caspase-3
found in Ddo/mice, we also detected a robust age-dependent
Figure2. DNAmethylation degree of theDdogeneduringmouse brain ontogenesis.a, Structure of the putativemouseDdogenepromoter. Arrow indicates the transcription start site (TSS,1).
White box represents the putative regulatory upstream region. Black box represents exon 1. Gray box represents first intron. Position of CpG sites is indicated as relative to TSS. Position of the primers
used for bisulfite analysis is indicated by arrows at the top of the map (Ddo PR1 fw, Ddo PR1 rev, and Ddo PR2 fw, Ddo PR2 rev). RR1 and RR2 indicate the amplicons used to analyze the regulatory
region 1 and 2, respectively.b, c, Graphs represent the percentage ofmethylation in (b) the single CpG sites and (c) the averagemethylation degree of the eight CpG sites included in the RR1 andRR2
regions, at the indicated developmental stages.Whole-brain samples used for themethylation analysis are the same as that used tomeasureDdomRNA relative expression (Fig. 1f ).d, RelativeDdo
mRNAexpression in primary cortical neurons obtained fromE17brains of C57BL/6Jmice, treatedwith vehicle (Veh) or 5M5-aza-2-deoxycytidine (azacitidine, Aza) for 48h. **p	0.01 (one-way
repeated-measures ANOVA). ***p	 0.0001 (one-way repeated-measures ANOVA). Data are mean SEM.
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activation of apoptotic events in the infralimbic/prelimbic area of
these animals (genotype, F(1,12)  1157.068, p 	 0.0001; geno-
type  age, F(2,12)  286.507, p 	 0.0001). Indeed, subsequent
post hoc analysis revealed a significantly higher percentage of
TUNEL-positive cells in 6- and 13-month-old Ddo/ mice,
compared with age-matched Ddo/ animals (6-month-old:
Ddo/, 27.03  1.76, Ddo/, 78.66  1.35; p 	 0.0001; 13-
month-old: Ddo/, 25.88  1.22, Ddo/, 79.29  1.01; p 	
0.0001; Fig. 4c,d).
Increased levels of D-aspartate inDdo/ brains are
associated with age-related appearance of dystrophic
microglia in the substantia nigra
We recently found that exogenous application of free D-Asp
mainly triggers NMDAR-dependent currents in dopaminergic
neurons of the substantia nigra pars compacta (Krashia et al.,
2015). Based on this observation, we used Ddo/ mice to ex-
plore whether also in the SN the physiological activity of DDO is
able to prevent neurotoxic insults produced by persistently ele-
vated free D-Asp during aging.
Before starting such characterization, we first measured free
D-Asp levels in the ventralmidbrain of adultDdo/ andDdo/
mice by HPLC. In line with the expression ofDdo in this cerebral
area (Fig. 1g), we found a significant 5-fold increase in free
D-Asp content in Ddo/ brains, compared with controls
(Ddo/: 1.30  0.10 nmol/mg protein, Ddo/: 5.82  0.24
nmol/mg protein; p 	 0.0001, Student’s t test; Fig. 5a). Con-
versely, no significant change between genotypes was detected in
free L-Asp levels (Ddo/: 30.19  1.51 nmol/mg protein;
Ddo/: 34.57  1.95 nmol/mg protein; p  0.1261; Fig. 5b).
Accordingly, the D-Asp/total Asp ratio significantly increased in
the midbrain of Ddo/ animals, compared with Ddo/ litter-
mates (Ddo/: 0.041  0.001; Ddo/: 0.145  0.008; p 	
0.0001; Fig. 5c).
Then, to assess the involvement of DDO in the physiological
aging process ofmidbrain dopaminergic neurons, we analyzed in
the SN of Ddo/ mice the number and morphology of micro-
glial cells (Fig. 5d–g), whose activation is considered as a reliable
marker of neuronal inflammatory/neurotoxic conditions (Streit
et al., 2009). To this aim, we used mice at different ages, ranging
from 0.5 to 13 months. Statistical analysis revealed a significant
effect of genotype on the total number of microglial cells (two-
way ANOVA, F(1,20)  7.803, p  0.0002; Fig. 5d). Subsequent
post hoc analysis showed a significantly higher number of total
microglia (mostly resting phenotype) in 0.5-, 3-, 10-, and 13-
month-old Ddo/ mice, compared with their respective age-
matched controls (0.5-month-old: Ddo/, 1.38  0.15 cells/
20,000 m2;Ddo/, 2.76 0.30 cells/20,000 m2, p 0.0147;
3-month-old: Ddo/, 1.66  0.19 cells/20,000 m2; Ddo/,
3.00  0.38 cells/20,000 m2, p  0.0366; 10-month-old:
Ddo/, 2.28  0.15 cells/20,000 m2; Ddo/, 3.66  0.10
cells/20,000 m2, p  0.0014; 13-month-old: Ddo/, 2.33 
0.10 cells/20,000 m2; Ddo/, 2.83  0.10 cells/20,000 m2,
p 0.0212; Fig. 4d).
Further, we assessed the number of reactive microglia, that
resulted to be differentially activated in Ddo/ and Ddo/
mice during aging (two-way ANOVA: genotype, F(1,20) 7.816,
p  0.0112; genotype  age, F(4,20)  3.552, p  0.0241; Figure
5e). Indeed, we found an increasing trend in the number of reac-
tive microglia in Ddo/ mice at 3, 6, and 10 months of age
(3-month-old: Ddo/, 0.11  0.11 cells/20,000 m2; Ddo/,
0.78 0.22 cells/20,000 m2, p 0.055; 6-month-old:Ddo/,
Figure 3. Increased extracellular levels of D-aspartate in the prefrontal cortex ofDdo/mice. a, Representative darkfield autoradiograms of sagittal sections showingDdomRNA expression in
the brain of Ddo/ and Ddo/mice at E15 and P60. Scale bar, 750m. b– d, D-aspartate (D-Asp) and L-aspartate (L-Asp) content in prefrontal cortex homogenates of Ddo/ and Ddo/
mice (n 5 per genotype), measured by HPLC. The average amounts of (b) D-aspartate and (c) L-aspartate detected during the analyses were normalized by the total protein content in the tissue
samples or (d) reported as D-aspartate/total aspartate ratio. ***p	 0.0001, compared with Ddo/ mice (Student’s t test). e– g, Average extracellular concentration of (e) D-aspartate, (f )
L-aspartate, and (g) L-glutamate (L-Glu) measured by HPLC in dialysates collected from the prefrontal cortex of freely moving Ddo/ and Ddo/mice (n 8 for D-aspartate and L-aspartate
detection, n 5 for L-glutamate detection) at different time-points (30–180min). Last fraction of dialysates (150–180min)was collected in a Ca 2-free ACSF. Amino acid extracellular levels are
expressed as nM (D-aspartate and L-aspartate) orM (L-glutamate) concentration. Data are mean SEM.
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Figure 4. Precocious activation of caspase-3 and cell death in the prefrontal cortex of Ddo/mice. a– d, Analysis of apoptotic markers in pyramidal neurons of the prefrontal cortex
of 3-, 6-, and 13-month-old Ddo/ and Ddo/mice (n 3 per genotype and age). a, Representative images showing activated caspase-3 (green) immunoreactivity in laminae II/III
of the infralimbic cortex of Ddo/ and Ddo/mice. Nuclei are counterstainedwith DAPI (blue). Bottom panels, Representative NeuN immunoperoxidase in 13-month-oldmice. Inset,
High magnification of the boxed area in the prelimbic (PL) region showing the reduction of number of NeuN-immunoreactive profiles in Ddo/ mice, compared with Ddo/
littermates. Highmagnification of NeuN/DAPI/caspase-3 immunofluorescence in laminae II/III of the infralimbic (IL) cortex of 13-month-old mice. Asterisks and arrow indicate caspase-3
immunoreactivity in neurons and in some non-neuronal cells, respectively. c, TUNEL staining (green) immunoreactivity in laminae II/III of the infralimbic cortex of Ddo/ and Ddo/
mice. Nuclei are counterstained with DAPI (blue). Scale bars: NeuN, 500 m; caspase-3, caspase3/DAPI, TUNEL, TUNEL/DAPI, 100 m; NeuN/DAPI/caspase-3, 8 m. b, d, Bar graphs
showing the percentage of (b) caspase-3- and (d) TUNEL-positive cells. ***p	 0.0001, compared with Ddo/ mice (Fisher’s post hoc). Data are mean SEM.
3072 • J. Neurosci., March 9, 2016 • 36(10):3064–3078 Punzo et al. • DdoMethylation Controls Cell Death during Aging
Figure 5. D-Aspartate detection in total homogenates and precocious appearance of dystrophic microglia in the midbrain of Ddo/mice. a– c, D-Aspartate (D-Asp) and L-aspartate (L-Asp)
content inmidbrain homogenates fromDdo/ andDdo/mice (n 4 per genotype),measured by HPLC analysis. The average amounts of (a) D-aspartate and (b) L-aspartate detected during
the analyses were normalized by the total protein content in the tissue samples or (c) reported as the D-aspartate/total aspartate ratio. ***p	 0.0001, compared with Ddo/mice (Student’s t
test). d– g, Morphological analysis of microglia in the substantia nigra of Ddo/ and Ddo/mice during ontogenesis (n 3 per genotype and age), evaluated by Iba-1 immunofluorescence.
Quantitative analysis of the (d) total, (e) hypertrophic, and (f ) dystrophic-like microglia at 0.5, 3, 6, 10, and 13 months of age. g, Immunofluorescence of Iba-1-positive microglial cells in the
substantianigraof 10- and13-month-oldDdo/andDdo/. At the lowestmagnification, the regionof the substantianigra is delimitedbyadottedoval. At thehighestmagnification, examples
are shownof resting, reactive, and dystrophic-likemicroglia identified in the substantia nigra of 13-month-oldDdo/mice. Scale bars: 200, 50, 25m. *p	 0.05, comparedwithDdo/mice
(Fisher’s post hoc). **p	 0.01, compared with Ddo/mice (Fisher’s post hoc). ***p	 0.0001, compared with Ddo/mice (Fisher’s post hoc). Data are mean SEM.
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0.27 0.15 cells/20,000 m2; Ddo/, 1.05 0.36 cells/20,000
m2, p  0.1186; 10-month-old: Ddo/, 0.16  0.09 cells/
20,000 m2;Ddo/, 0.50 0.10 cells/20,000 m2, p 0.0700;
Fig. 5e) and, conversely, a trend decline in 13-month-old knock-
outs, compared with wild-type littermates (Ddo/, 0.44 0.11
cells/20,000 m2; Ddo/, 0.11  0.06 cells/20,000 m2, p 
0.0550; Fig. 5e).
Finally, we counted the number of dystrophicmicroglia, char-
acterized by fragmented cell body andprocesses, which is thought
to be predictive of neuronal damage, as reported also in Alzhei-
mer’s disease human brain (Streit et al., 2009). Consistent with
the neurotoxic effect of deregulated D-Asp levels, we found an
age-related appearance of dystrophic microglia in the SN of
Ddo/ mice, which was not detected in Ddo/ controls (two-
way ANOVA: age, F(4,20) 70.502, p	 0.0001; genotype, F(1,20)
165.302, p 	 0.0001; age  genotype, F(4,20)  53.456, p 	
0.0001; Figure 5f). In particular, we evidenced a significant
occurrence of dystrophic microglia specifically in 10- and 13-
month-old Ddo/ mice, compared with their respective age-
matched controls (10-month-old: Ddo/, 0.11  0.05 cells/
20,000 m2;Ddo/, 2.50 0.17 cells/20,000 m2, p 0.0002;
13-month-old: Ddo/, 0.22  0.22 cells/20,000 m2 Ddo/,
2.27 0.06 cells/20,000 m2, p 0.0009; Fig. 5f,g).
Increased levels of free D-aspartate trigger age-related
caspase-3 activation and cell death in dopaminergic neurons
of the substantia nigra
Based on the abnormal appearance of dystrophic microglia, we
explored whether the constitutive upregulation of free D-Asp lev-
els in Ddo/ brains also triggered the activation of apoptotic
pathway and cell death in TH-positive neurons of the SN. To this
aim, we evaluated the expression levels of active caspase-3 in 0.5-,
3-, 6-, 10-, and 13-month-old Ddo/ mice. Interestingly, we
found a significant genotype-dependent variation in the percent-
age of active caspase-3-positive cells (two-way ANOVA: geno-
type, F(1,20)  214.010, p 	 0.0001; age  genotype, F(4,20) 
22.902, p 	 0.0001). Accordingly, post hoc analysis revealed a
higher expression of active caspase-3 already in 3-month-old
and,more substantially, also in 6-, 10-, and 13-month-old knock-
out animals, compared with their respective age-matched con-
trols (3-month-old: Ddo/, 14.16  1.12%, Ddo/, 18.40 
0.81%, p  0.0375; 6-month-old: Ddo/, 18.57  1.45%,
Ddo/, 36.66  2.35%, p  0.0028; 10-month-old: Ddo/,
19.99 2.05%,Ddo/, 45.42 0.50%, p 0.0003; 13-month-
old: Ddo/, 19.34  2.47%, Ddo/, 49.52  2.41%, p 
0.0009; Fig. 6a,b, arrows).
Finally, we detected TUNEL staining in the SN of 3-, 6-, and
13-month-old Ddo/ mice. In agreement with previous results
found in the PFC, we revealed that the number of TUNEL/TH-
positive neurons in this brain region of Ddo/ mice significantly
increased with age (two-way ANOVA: genotype, F(1,12) 214.764,
p 	 0.0001; genotype  age, F(2,12)  44.238, p 	 0.0001). The
following post hoc analysis showed a higher percentage of positive
cells in 6- and 13-month-old Ddo/ mice, compared with age-
matched controls (6-month-old: Ddo/, 21.28  1.06, Ddo/,
41.65  1.16, p  0.0002; 13-month-old: Ddo/, 21.83  0.93,
Ddo/, 47.93 1.75, p 0.0002; Fig. 6c,d).
Overall, our data indicate that physiological enzymatic activity of
DDO in the brain has a relevant neuroprotective effect able to pre-
vent abnormal accumulation of extracellular free D-Asp that would
otherwise trigger precocious degenerative events during aging.
Increased extracellular levels of free D-aspartate elicit
precocious age-related accumulation of lipofuscin inDdo/
brains
To investigate the presence of oxidative stress as a consequence
of persistent upregulation of free D-Asp levels, we assessed in
Ddo/ mice the levels of lipofuscin deposition, an auto-
fluorescent pigment that accumulates over time and that posi-
tively correlates with the rate of aging (Brunk and Terman, 2002;
Riga et al., 2006). Interestingly, lipofuscin accumulation was not
yet detectable either in the SN (Fig. 7a) or in the PFC (data not
shown) of both genotypes at preweaning stage (0.5 months).
Conversely, in both the SN and in the layers V-VI of the PFC of
adult Ddo/ animals (3 months), we observed a significant in-
crease of the total volume of lipofuscin inclusion bodies com-
pared with Ddo/ mice (Fig. 7a,b; p 	 0.05, Student’s t test).
The precocious accumulation of lipofuscin in the Ddo/ brain
suggests that persistent elevation of D-Asp levels triggers greater
oxidative stress and further supports the role of aberrant D-Asp
metabolism on the early neurodegenerative events found in
mutants.
Discussion
In the present work, we first demonstrated conserved age-related
reduction of free D-Asp levels in the mouse brain, in line with
previous observations in rats and humans (Hashimoto et al.,
1993; Schell et al., 1997; Sakai et al., 1998; Wolosker et al., 2000).
In addition, we showed a remarkable age-related increase inDdo
mRNA levels that is in line with the previously reported postnatal
enhancement in DDO activity (Van Veldhoven et al., 1991) and
the progressive decrease in free D-Asp levels. This evidence sug-
gests that the ontogenetic changes in Ddo mRNA expression are
most likely able to control, as net effect, the actual concentration
of free D-Asp in the brain. Consistently, we have recently found
that reduced levels of free D-Asp in the PFC of patients with
schizophrenia (Errico et al., 2013) are associated with increased
levels of Ddo mRNA, compared with healthy subjects (Errico et
al., 2015b). Interestingly, we also found that the temporal in-
crease in postnatal Ddo mRNA levels is mirrored by a concomi-
tant and progressive demethylation of Ddo gene regulatory
region surrounding the TSS. To unveil the causal relationship
between demethylation of the putative Ddo promoter and in-
creased Ddo transcription, we tested the effect of the DNA-
demethylating agent azacitidine in primary neuronal culture
from embryonic brain, when the physiological expression of this
gene is nearly undetectable. Interestingly, the evidence that azaci-
tidine induces an 4-fold increase in Ddo mRNA levels, com-
pared with vehicle-treated controls, indicates the existence of a
finely tuned demethylation process at the basis of the observed
postnatal increase in Ddo gene expression. In this view, we argue
that the epigenetic changes within the Ddo regulatory region
herein investigated are part of a developmental program to reg-
ulate the timed expression of the Ddo gene during prenatal and
postnatal brain development. On the other hand, ISH clearly
indicated that postnatal transcriptional activation of Ddo gene
differs from one brain area to another, suggesting that Ddo pro-
moter demethylation occurs with a peculiar spatiotemporal pat-
tern to properly regulate the regional postnatal occurrence of
DDO and, ultimately, free D-Asp concentrations.
Despite pharmacological, neurophysiological, and behavioral
data indirectly asserting a role for free D-Asp in modulating glu-
tamatergic system (Errico et al., 2012, 2015a), the basal cerebral
content of this D-amino acid has long been considered too low to
justify a neurobiological implication at adulthood. Herein, by
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means of microdialysis studies performed in the PFC of freely
moving animals, we demonstrated the occurrence of nanomolar
concentrations of extracellular free D-Asp in controls (20 nM)
and, most interestingly, an increase of5 times of this D-amino
acid content in knock-out mice. Moreover, in agreement with
previous in vitro studies (Davies and Johnston, 1976; Malthe-
Sørenssen et al., 1979; Nakatsuka et al., 2001; Savage et al., 2001;
Raiteri et al., 2007; D’Aniello et al., 2011), we found that endog-
enous free D-Asp is released also in vivo by neurons through a
Ca2-dependent mechanism, as extracellular concentration of
this D-amino acid is below the detection limit in Ca2-free con-
dition. Unexpectedly, we also detected increased extracellular
L-Asp levels in Ddo/mice but unchanged total content of the
L-isomer, as reported also in other studies (Errico et al., 2006;
Han et al., 2015). In the attempt to explain such an interesting
result, we hypothesize that exaggerated intracellular accumula-
tion of free D-Aspmay locally alter the racemization rate of D-Asp
to L-Asp in the cortical nerve terminals and/or affect the mecha-
nism of L-Asp release and uptake. Unlike extracellular D-Asp and
L-Asp, we did not find any difference in the extracellular levels of
L-Glu detected in the PFC of Ddo/ and Ddo/ mice. How-
ever, as shown for free D-Asp, the release of both L-Asp and L-Glu
was suppressed in dialysates without Ca2. Although this effect is
expected for classical neurotransmitters, the in vivo evidence of
free D-Asp clearance suggests that this D-amino acid can be ac-
tively and efficiently removed from the extracellular space, likely
Figure6. Precocious activation of caspase-3 and cell death in the substantia nigra ofDdo/mice.a– d, Analysis of apoptoticmarkers in TH-positive neurons of the substantia nigra ofDdo/
and Ddo/mice during ontogenesis (n 3 per genotype and age). a, c, Representative images showing (a) activated caspase-3 immunoreactivity or (c) TUNEL staining immunoreactivity in
TH-positive neurons from 3-, 6-, and 13-month-old Ddo/ and Ddo/mice (n 3 per genotype and age). Arrows indicate some of these neurons. Asterisks indicate representative areas,
including TH-positive neuronal apoptotic debris. Insets, Lowmagnifications of the substantia nigra showing a significant reduction of TH immunodensity inDdo/, comparedwithDdo/mice,
more evident in aged Ddo/mice. Scale bars: insets, 200m; TH/caspase-3, caspase-3, TH/TUNEL, TUNEL, 50m. b, d, Bar graphs represent the percentage of (b) caspase-3/TH-positive cells
(0.5-, 3-, 6-, 10-, and 13-month-old Ddo/ and Ddo/mice) or (d) TUNEL/TH-positive cells (3-, 6-, and 13-month-old Ddo/ and Ddo/mice). *p	 0.05, comparedwith Ddo/mice
(Fisher’s post hoc). **p	 0.01, compared with Ddo/mice (Fisher’s post hoc). Data are mean SEM.
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through L-Glu/L-Asp transport system, which has been previ-
ously shown tomediate the in vitro uptake of bothAsp enantiom-
ers approximately with the same affinity (Arriza et al., 1994, 1997;
Palacín et al., 1998).
Despite that the existence of enzymes catalyzing the degrada-
tion of D-amino acids is long established (Krebs, 1935), the role of
DDO in the brain has been puzzling because of the negligible
levels of its endogenous substrates. Importantly, herein we report
that DDO exerts its physiological role by protecting the brain
from the neurotoxic effects induced by persistently higher extra-
cellular levels of its substrate, D-Asp, known to act as an NMDAR
agonist. Indeed, consistent with the knowledge that sustained
overactivation of NMDARs at extrasynaptic sites is detrimental
for neuronal survival (Lipton, 2008; Hardingham and Bading,
2010; Parsons and Raymond, 2014), we showed that the lack of
DDO in knock-out mice, through the resulting persistent spill-
over of extracellular D-Asp, triggers precocious oxidative stress,
activation of caspase-3, and cell death in the PFC and SN. Inter-
estingly, coexpression of activated caspase-3 with NeuN in the
PFC, andwith TH in the SN, demonstrates that cell death in these
brain areas of Ddo/mice involves pyramidal and dopaminer-
gic neurons, respectively. On the other side, active caspase-3
immunoreaction is also, to some extent, detected outside NeuN-
and TH-positive neurons, thus suggesting that apoptotic events
triggered by increased D-Asp levels are not exclusive of these cell
types.
Previous findings have demonstrated that D-Asp is the best
substrate for human and mouse DDO, followed by NMDA
(Setoyama and Miura, 1997; Katane et al., 2015a). Indeed, the
mouse enzyme is also active on D-Glu and D-asparagine, but the
relative activity is only 3.7% and 1.3% of the one determined for
D-Asp (no activity was instead detected on D-histidine and other
D-amino acids). Accordingly, it is conceivable that the activity of
mouse DDO is too low to affect the cellular levels of these alter-
native substrates that, in turn, cannot contribute to the pheno-
types observed in Ddo/ mice. In addition to D-Asp, we have
previously reported increased endogenous levels of NMDA in
brain Ddo/ homogenates. However, the content of NMDA in
knock-out brains is hundreds-fold lower than D-Asp (Errico et
al., 2006, 2011c). Therefore, we think that the contribution of this
molecule to the overstimulation of NMDARs inDdo/ brain is
likely negligible compared with that produced by the massive
accumulation of free D-Asp.
Neurodegenerative events in knock-out mice are accompa-
nied by substantial changes inmicroglia morphology. Indeed, we
found in the SN an age-dependent phenotypic shift of microglia
from hypertrophic toward a dystrophic one. This could be ex-
plained assuming that, in an early stage (3, 6 months), reactive
microglia are in charge with the removal of high caspase-3-
positive apoptotic cells, including clusters of lipopigments, such
as lipofuscin (Riga et al., 2006), thus becoming overloaded and
dystrophic in a late phase (10, 13 months). Strikingly, the obser-
vation of dystrophic microglia in a mouse model is quite a rare
finding because this kind of cell does not appear with aging in
rodents, as they do in humans during aging and in aging-related
neurodegenerative disorders, including Alzheimer’s disease (St-
reit and Xue, 2014; Streit et al., 2014).
Together, these data are coherent with previous morphologi-
cal, functional, and in vivo observations indicating that const-
itutively upregulated levels of D-Asp in aged (6-month-old
onwards) Ddo/mice lead to the progressive decay of synaptic
transmission and plasticity, ERK signaling, cognitive abilities,
and increased sensitivity to phencyclidine-induced prepulse in-
hibition deficit (Errico et al., 2011b; Cristino et al., 2015). Con-
versely, higher free D-Asp content in young-adult Ddo/ mice
has beneficial NMDAR-mediated effects because it enhances hip-
pocampal early- and late-phase LTP (Errico et al., 2008b, 2011b,
Figure 7. Increased age-dependent lipofuscin accumulation in the substantia nigra pars
compacta and prefrontal cortex ofDdo/mice. a, Representative high-magnification confo-
cal images of the substantia nigra pars compacta and prefrontal cortex (layers V-VI) ofDdo/
and Ddo/mice at 0.5 and 3 months of age (n 3 per genotype and age). Higher accumu-
lation of lipofuscin granules (red) appears evident in 3-month-old Ddo/ compared with
Ddo/ specimens in both TH-immunostained (green) dopaminergic neurons as well as in
deep layers (V-VI) of the prefrontal cortex. b, Quantification of lipofuscin inclusion bodies vol-
ume in the substantia nigra and prefrontal cortex. Data aremean SEM. n.d., Nondetectable.
*p	 0.05, compared with Ddo/mice (Student’s t test). Scale bar, 5m.
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2014), ERK phosphorylation (Errico et al., 2011b), and dendritic
length and spine density (Errico et al., 2014), ameliorates spatial
memory (Errico et al., 2008a, 2011b), and reduces prepulse inhi-
bition deficits produced by psychotomimetic drugs, such as am-
phetamine, MK801, and phencyclidine (Errico et al., 2008a,
2015b). The opposite phenotypes shown by Ddo/ mice at
different phases of postnatal life highlight the peculiarity of
this animal model to reproduce the dichotomous behavior of
NMDAR signaling, which is able to promote synaptic plasticity
and cognition or excitotoxicity depending on the subcellular lo-
calization (synaptic vs extrasynaptic activation). Further studies
are needed to investigate how constitutive increase of free D-Asp
can trigger synaptic or extrasynapticNMDAR signaling in a time-
dependent manner.
Notably, the abnormal precocious cell death produced by
constitutively elevated free D-Asp levels in Ddo/ brains sug-
gests that DDOmay control the vulnerability to neurodegenera-
tion by hindering the endogenous accumulation of its substrate.
Conversely, the physiological abundance of free D-Asp in the
embryonic and perinatal brain, due to negligible Ddo expression
and enzyme activity (Van Veldhoven et al., 1991), indicates that
the physiological role of D-Asp must be restricted to a limited
developmental time window, after which its high content would
be harmful. In this regard, it is mandatory that the generation of
conditional Ddo/ mice and the employment of inhibitors for
DDO enzyme (Katane et al., 2015b) to test the safety of transient
D-Asp increase (as opposed to the detrimental effects of its per-
sistent elevation) in the adult brain.
In conclusion, our results show, for the first time, that the
progressive demethylation of the putative Ddo promoter is the
mechanism for the postnatal onset and subsequent increase of
Ddo expression that, in turn, is critical to regulate the content of
the NMDAR agonist, D-Asp, in adulthood. In a mouse model
with constitutively suppressedDdo expression, we demonstrated
that deregulated extracellular levels of D-Asp are able to produce
early oxidative stress and cell death, thus unmasking a key role for
DDO in counteracting precocious neurodegeneration produced
by excessive NMDAR stimulation. In this light, Ddo/ mice
represent a novel animal model of accelerated brain aging dete-
rioration with potential application for in vivo screening of anti-
aging compounds.
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